

Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycaemic Targets in Paediatric and Adult Participants With Type 1 Diabetes

- **Clinical objective:** to evaluate the safety and efficacy of the Omnipod[®] 5 Automated Insulin Delivery (AID) System, the first tubeless, on-body AID system with customizable glycaemic targets.
- **Primary end points** were change in HbA1c at the end of the AID phase compared with baseline and Time in Range 70–180 mg/dL (3.9-10.0 mmol/L) during the AID phase compared with the Standard Therapy (ST) phase. Primary safety outcomes were incidence of severe hypoglycaemia and diabetic ketoacidosis (DKA).
- **Secondary end points** included percent time with glucose levels <70 mg/dL (<3.9 mmol/L), >180 mg/dL (>10.0 mmol/L) and <54 mg/dL (<3.0 mmol/L) during the AID phase compared with the ST phase.
- **Significant improvements** in HbA1c and glycaemic measures, with a low rate of hypoglycaemia in a heterogeneous participant group with varied age, baseline glycaemia and prior insulin delivery regimen.

Study Design


- Prospective, multicenter, single-arm outpatient study:
 - 14-day standard therapy phase
 - 3-month AID phase with Omnipod 5 system
- 240 children, adolescents and adults enrolled at 17 institutions across the US
- User-selected target glucose ranges from 110-150 mg/dL (6.1-8.3 mmol/L)
- Unrestricted diet and exercise throughout

Study Participants

- 112 Children: Age 6 to <14 years
- 128 Adolescents and Adults: Age 14 to 70 years
- All participants:
 - Type 1 diabetes for ≥ 6 months
 - HbA1c <10.0% (<86 mmol/mol)
 - Any prior insulin therapy (MDI or CSII)

Omnipod 5 System reduced HbA1c

HbA1c is reduced by 0.38% (4.2 mmol/mol) in Adolescents and Adults¹



Participant endorsement of the system was evident, with 95% enrolling in the extension phase.


● Standard Therapy phase ● Omnipod 5 System phase

* p<0.0001; † p=0.046. Baseline and follow-up data were used for the HbA1c primary endpoint. Data shown for Standard Therapy phase and AID phase.

Data shown as mean HbA1c.

MDI, multiple daily injections with insulin.

HbA1c is reduced by 0.71% (7.8 mmol/mol) in Children¹



Connectivity of the on-body devices was excellent, allowing use of automated insulin delivery for median 96.4% of possible time for children.

● Standard Therapy phase ● Omnipod 5 System phase


* p<0.0001; † p<0.0005. Baseline and follow-up data were used for the HbA1c primary endpoint. Data shown for Standard Therapy phase and AID phase.

Data shown as mean HbA1c.

MDI, multiple daily injections with insulin.

Omnipod 5 System increased Time in Range (TIR)

- TIR is improved by 2.2 hours/day (9.3%) in Adolescents and Adults¹
- TIR is improved by 3.7 hours/day (15.6%) in Children¹




Children spent median 96.4% and adults/adolescents spent median 96.7% of total study time in automated mode.

● Standard Therapy phase ● Omnipod 5 System phase

* p<0.0001. Data shown as mean %TIR

Reduced hypoglycaemia in adolescents and adults, with low remaining hypoglycaemia in children

- Hypoglycaemia is reduced by 46% in Adolescents and Adults¹
- Hypoglycaemia remains low in children



● Standard Therapy phase ● Omnipod 5 System phase

* p<0.0001. Data shown as median %Time Below Ranges <70 mg/dL and <54 mg/dL

Study Highlights:¹

Reduced HbA1c

- Omnipod 5 System lowered HbA1c by 0.38% (4.2 mmol/mol) in Adolescents/Adults, and by 0.71% (7.8 mmol/mol) in Children
- 66% of Adults/Adolescents and 53% of Children achieved the ADA recommended HbA1c target of <7.0% (<53 mmol/mol)

Increased Time in Range (TIR)

- Improved TIR by 2.2 hours/day (9.3%) in in Adolescents/Adults, and by 3.7 hours/day (15.6%) in Children
- 82% of Children and 69% of Adults/Adolescents met consensus clinical targets for TIR
- All age groups demonstrated 78% TIR overnight from 00:00–06:00 h during the study

Low time in hypoglycaemia

- Omnipod 5 System reduced time in hypoglycaemia by 46% in Adults and Adolescents, including a 60% reduction in nocturnal hypoglycaemia (00:00–06:00 h)
- Time in hypoglycaemia remained low throughout the study in Children

System use

- Children spent median 96.4% and Adults/Adolescents spent median 96.7% of total study time in automated mode
- Incidence of severe hypoglycaemia and DKA were below reported rates in the US T1D Exchange Registry and were not attributable to AID malfunction



Scan code to view
published study



This summary has been provided as part of the Omnipod Academy, an educational service provided for Healthcare Professionals by Insulet International.



Omnipod System
availability guide



Please contact Geffen
Medical representative
for more information

References 1. Adapted from; Brown SA, et al. Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycemic Targets in Pediatric and Adult Participants With Type 1 Diabetes. Diabetes Care 2022; 44:1630-1640.

©2024 Insulet Corporation. Omnipod and the Omnipod logo are trademarks or registered trademarks of Insulet Corporation in the United States of America and other various jurisdictions. All rights reserved. All other trademarks are the property of their respective owners. The use of third party trademarks does not constitute an endorsement or imply a relationship or other affiliation. Insulet Netherlands, B.V., Stadsplateau 7, 3521 AZ Utrecht, Netherlands